Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Convulsive therapy in schizophrenia?

M Fink1, H A Sackeim

  • 1State University of New York, School of Medicine, Stony Brook, USA.

Schizophrenia Bulletin
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 'difficult-to-treat depression' and the 'response paradigm' models: Implications and relevance to patient management.

The Australian and New Zealand journal of psychiatry·2021
Same author

A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.

Neurology·2007
Same author

Strengthening clinical effectiveness trials: equipoise-stratified randomization.

Biological psychiatry·2001
Same author

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2001
Same author

Vagus nerve stimulation in depression.

Expert opinion on pharmacotherapy·2001
Same author

Focal prefrontal seizures induced by bilateral ECT.

The journal of ECT·2001
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

Electroconvulsive therapy (ECT) is an effective treatment for schizophrenia, particularly for first-break episodes and specific symptom clusters. This therapy offers a valuable option for patients resistant to other treatments.

Area of Science:

  • Psychiatry
  • Clinical Neuroscience

Background:

  • Schizophrenia is a complex disorder with evolving treatment paradigms.
  • Electroconvulsive therapy (ECT) was an early treatment for schizophrenia, later superseded by psychotropic medications.
  • Reintroduction of ECT in the 1970s focused on therapy-resistant conditions.

Purpose of the Study:

  • To reassess the current role and efficacy of ECT in managing schizophrenia.
  • To identify specific patient subgroups within schizophrenia who may benefit most from ECT.

Main Methods:

  • Review of historical and contemporary literature on ECT for schizophrenia.
  • Assessment of clinical outcomes and applicability in various schizophrenia presentations.

Main Results:

Related Experiment Videos

  • ECT is identified as an effective treatment for psychotic symptoms in schizophrenia.
  • Particular efficacy is noted in first-break episodes, especially those with excitement, overactivity, delusions, or delirium.
  • ECT is beneficial for young patients to prevent chronic illness effects and for catatonia, positive symptoms, or schizoaffective features.

Conclusions:

  • ECT remains a viable and effective treatment option for specific patient populations with schizophrenia.
  • Its application is particularly relevant in acute phases and for therapy-resistant or complex presentations.